Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
RVTY enters the final stretch before its November 3 earnings with a stock up 18% in a month, short sellers quietly adding to positions, and the Street split on whether the rally has outrun the fundamentals.
The most notable move this week came from the Street, not the lending market. Barclays analyst Luke Sergott raised his price target on RVTY to $160 from $115 on October 7, while keeping an Equal-Weight rating, a 39% lift to the target that still stops short of a bullish call. William Blair separately initiated coverage with an Outperform. Those two actions sit alongside UBS, which stepped down from Buy to Neutral last month after assuming coverage, setting a $140 target. The mean analyst target across the group is $137.53, which sits about 10% below where the stock trades at $153.30. Keybanc has the most constructive view on the Street with a $165 Overweight target, but the cluster of Equal-Weight and Neutral ratings from Barclays and UBS reflects a broader sense that the stock's 18% one-month surge has compressed the margin of safety bulls would want.
The positioning picture supports that cautious framing. Short interest has climbed roughly 8.5% over the past week to 5.6% of the free float, a meaningful rebound after a month in which SI had drifted lower. The build is steady: from around 5.87 million shares in late September to 6.37 million now. Borrow conditions remain easy despite the uptick. The cost to borrow has eased to 0.45%, down 14% on the week, and borrow availability is wide at roughly 409%, meaning there are more than four shares available in the lending pool for every share currently shorted. That level of availability is well above the 52-week trough of 156%, signalling the short build is not being constrained by supply. Options positioning, meanwhile, is modestly bullish: the put/call ratio at 0.54 is slightly below its 20-day average of 0.60, and the z-score of negative 0.41 places sentiment close to neutral rather than defensively positioned. Together, the picture is of shorts pressing a directional view while options traders remain relaxed.
The bull and bear debate maps neatly onto the analyst divide. Bulls point to Revvity's Life Sciences segment as a pure-play on pre-clinical R&D, with improving biotech funding and early AI-driven screening demand translating into multi-system orders and high incremental margins on reagents and antibodies. The EUROIMMUN autoimmune franchise and the newborn screening business, which covers tens of millions of babies across more than 100 countries, add recurring, contract-backed revenue with high switching costs. Bears counter that organic growth is running below the company's own 6-8% target, with consensus estimates at roughly 4.9% for FY26 and 5.1% for FY27. Adjusted operating margins are modelled at 28 to 29%, well short of the mid-30% goals, while softer momentum in Euroimmun and the Genomics England contract anniversary in Q4 create near-term comparison pressure. The valuation is not demanding by growth-stock standards, with the P/E at 26.6x and EV/EBITDA at 20.5x, the latter down about 0.7 points over 30 days, but the ORTEX factor scores underline the lack of value support: the EV/EBIT rank sits in the 20th percentile.
On ownership, T. Rowe Price remains the largest holder with around 14% of shares, though T. Rowe Price Investment Management's 13G filings show it trimmed from 16.4% to 9.2% of class in its most recent disclosure, filed in September. EdgePoint Investment Group, with 7.7% of shares, and Janus Henderson at 7.7%, have both been adding. Dimensional Fund Advisors added over 510,000 shares in the most recent reported period. Insider activity is limited and noise-free: all three recent transactions were small, pre-arranged 10b5-1 plan sales, with no open-market purchases in the 90-day window.
Retail attention has ticked up, with RVTY's Wikipedia and ORTEX page-view z-score running at 1.6, above its own 90-day history, though that dataset carries no measured link to the company's financials. The ORTEX short score has crept from 46.2 to 49.0 over the past two weeks, still in neutral territory but at its highest reading in that period. With earnings 27 days out, the key question is whether the organic growth trajectory in Q3 vindicates the stock's sharp recovery or hands the bears the confirmation they are currently paying to position for.
See the live data behind this article on ORTEX.
Open RVTY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
